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D 6 Clinical Trial Issues in Critical Limb Ischemia
D 6.1 Introduction
D 6.1.1 Scope
As with Clinical Trial Issues in Intermittent Claudication (B 6, P 5127), this section is not
intended to be exhaustive but rather focuses on selected controversial issues. Similarly, recom-
mendations made here are usually not based on solid scientific evidence, which is rare in this
area of trial methodology. In patients with CLI, trials involving surgical or endovascular tech-
niques as well as drug therapy are usually relevant. "Trial" in this context is taken to mean a
study designed to investigate the possible efficacy of one treatment modality compared with
another. This definition of a trial would exclude a purely descriptive account of a particular
treatment as presented in most publications on new surgical or endovascular techniques. Trials
in CLI are very rarely performed in the context of a randomized comparison between a new
technique and an established technique. Therefore, in assessing the efficacy for a new intcrven-
tional technique, one usually has to fall back on historical comparisons with studies describing
previous techniques. The reliability of such comparisons depends crucially on the accuracy of
description, that is, reporting standards (see later discussion).
The principal threat to patients with CLI as far as their legs are concerned is failure to relieve
ulceration, gangrene, or rest pain, leading to the need for a major amputation. Therefore, only
trials primarily designed to look at the efficacy of a new treatment in the context of limb salvage
will be considered. Patients with chronic CLI also have a higher risk of cardiovascular mortality
and morbidity (see Epidemiology, Natural History, Risk Factors, A 2, P 55). The role of meta-
analysis and decision modeling as an alternative is considered in Economic Aspects ofPAD (A 4,
P 545). After a general discussion of the problems involved in defining entry criteria and out-
come response in all trials in patients with CLI, special issues relating to interventional trials and
drug trials are discussed. For several decades, patients with CLI could be treated successfully only
by surgery. Most published studies on the treatment of CLI are descriptive accounts of a particu-
lar technique with no comparative group and, until recently, not using a standardized method of
reporting. Over the last 10 to 15 years, a number of publications have described endovascular
techniques, a few comparing them in randomized series with surgical alternatives. Trials ofphar-
rnacotherapy are even more recent and usually follow the conventional methodology of a ran-
domized controlled trial.
There have been no published trials of pharmacotherapy versus an interventional treatment in
patients with CLI. This is partly because no pharmacotherapy has yet been perceived to be pos-
sibly as effective as an alternative interventional technique, although this has never been tested.
Such a comparative trial would pose special problems in terms of deciding appropriate end
points because pharmacotherapy thar may promote healing in a critically ischaemic limb may
also have a systemic effect in reducing cardiovascular mortality and morbidity. Conversely, the
benefits of an interventional treatment are likely to be confined to the leg. Nevertheless, these
three alternative treatment modalities should be properly compared because, from the patientfs
point of view, the ultimate aim and therefore end point is the same: to avoid mortality and car-
diovascular morbidity while preserving an intact and painless limb. The current text and recom-
mendations take into account the outcome of the recent Trans-Atlantic Conference on Clinical
Trial Guidelines in PAOD:Clinical Trial Methodology.'
D 6.1.2 Trial Design
As in all diseases, ideally trials should be double-blind, randomized, and compared with placebo
or an existing treatment of proven efficacy. This ideal can only be approximated in intervention-
al trials. Similarly trials between different treatment modalities, for example, comparing devices
with pharmacotherapy, cannot be blinded. However, all trials involving patients with CLI have
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common features, such as issues relating to entry criteria and outcome assessment. These are
considered in the next two sections. Another feature that they have in common is that the new
treatment should be assessed against a background of a standard basic therapy, such as
antiplatelet agents, as described earlier (D 4.3.3, Pharmacotherapy Other Than Prostanoids, p
5199). For instance, treatment of concomitant illnesses such as cardiac failure should continue
as well as standard local treatment.
D 6.2 Entry Criteria for Randomized Trials
In contrast to trials in Ie, the principal problem with CLI is the entry criteria, whereas deciding
the relevant end point is much easier. The latter clearly has to be some combination of healing
of ulcers, relief of rest pain, and avoiding a major amputation, as well as consideration of general
cardiovascular morbidity and mortality. The problem with deciding entry criteria is that the risk
of continuing tissue necrosis and rest pain varies widely from patient to patient, and therefore
the risks of requiring a major amputation also vary. It is also necessary to consider briefly the
factors affecting the progression of CLI.
D 6.2.1 Progression of eLI
The factors affecting the progression of CLI are discussed in detail elsewhere (A 2.6, Critical
Limb Ischemia, p S20). These include the local blood pressure and perfusion, usually measured
as Doppler systolic pressure at the ankle or the toes, and the TCP02 . Furthermore, a variety of
clinical features, including diabetes and the morphology of the arterial lesion, affect clinical pro-
gression. Some studies have looked at these variables in relation to the progression of CLI.
Their influence is often dependent on whether a patient merely has rest pain or has areas of tis-
sue necrosis as well. For instance, the absolute ankle systolic pressure is predictive of the need
for a major amputation in patients with rest pain alone, but less so in patients who also have tis-
sue necrosis.s It is thus possible to describe a subgroup of patients with CLI, on the basis of
Doppler pressure or the TCP02 , in whom, in the absence of a dramatic improvement in blood
flow, a major amputation is inevitable. It is therefore possible to limit entry into a trial to those
patients in whom major amputation is almost certainly going to be necessary in the absence of a
major hemodynamic improvement.
Some of the debate over limits of ankle systolic pressure for entry is caused by confusion about
the purpose of such measurements. They can be used merely to establish that the patientfs skin
necrosis or pain is predominantly caused by arterial disease, in which case the cut-off in these
measurements can be relatively high. Alternatively, they can be used to predict the almost
inevitable need for a major amputation in the absence of successful treatment, in which case
limits will need to be much lower. There is no argument that they should almost certainly be
used for the former purpose, mat is, to establish that the patientfs symptoms are attributable to
arterial disease. This can be important, particularly in the case of rest pain, which can be caused
by a number of nonarterial causes, such as diabetic sensory neuropathy. The issue of using these
measurements to predict prognosis raises the controversy between inclusive and exclusive entry
criteria, which has already been discussed in the context of trials in IC.
D 6.2.2 Inclusivity Versus Exclusivity
Whether an inclusive set of entry criteria should be used to include a range of patients with dif-
ferent degrees of disease severity, or a set of exclusive criteria that defines a small, tight group of
patients with very similar disease and prognosis, is controversial. The arguments in favor of each
approach are more stark in CLI than in IC. Arguments in favor of exclusivity are:
• Patients entered form a homogenous group.
• Patients are clearly defined.
• Differences between treatment and control group in terms of demographic or other charac
teristics, which are known to affect a treatment result, are largely eliminated.
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• At least theoretically, the trial conditions are clearly defined and should be repeatable with
similar results in other centers.
• The expected outcome in the control group is almost defined in the entry criteria, that is,
limb loss. Any preservation of limb in the treatment group is likely to be important.
Arguments in favor of inclusivity are:
• The more inclusive the study, the more it reflects real life.
• Recruitment is easier, and fewer study centers are required.
• In practice, if the result of the study is positive, the new treatment is likely to be applied to
all patients with CLI. It should therefore be demonstrated to be effective in all patients,
unless there is a good reason to exclude a particular subgroup.
There are two other powerful arguments against an exclusive requirement for entry. If only
those patients are entered who are almost certain to go on to major amputation in the absence
of a dramatic improvement in blood flow, there is a danger that most patients entered already
have irreversible ischemic changes. In such patients, no treatment could possibly succeed in
avoiding amputation. The second argument against an exclusive entry qualification is that the
number of patients with CLI presenting to even a large vascularcenter is relativelysmall. With
very strict entry criteria, many centers will only be able to enter one patient per month at best.
Such a recruitment rate, with its attendant need for a large number of centers, raises a whole
new set of problems. A possible set of relatively inclusive entry criteria could be (1) rest pain,
ulcers, or gangrene caused by PAD, (2) an ABPI ofless than 0.7 or an article toe pressure index
ofless than 0.4, or, alternatively, a TCP02 of less than 30 mm Hg.
Repeated from p S170
Recommendation 74: Trials and reportin.u standards th,finition ofcritical limb ischemia
A relatively inclusive entry criterion is favored, the aim being to ensure that the ulceration,
gangrene, or rest pain is indeed caused by peripheral arterial disease and that most would be
expected to require a major amptttation within the next 6 months to a year in the absence ofa
significant hemodynamic improvement: To achieve this, it is suggestedto use absolute pres-
sures ofeither
ankle pressure < 50-70 mm Hg or
reduced toe pressure (dO-50 mm Hg) or
reduced TCP02 (dO-50 mm Hg)
Much confusion has arisen in the past from the entry criteria to a CLI trial being equated with a
clinical definition of CLI. This issue is discussed in detail in Nomenclature, D 1.1 (p S168),
concluding that the term CLI should be used for routine clinical purposes to include all patients
with ischemic rest pain and patients with ischemic ulcers or gangrene caused by PAD. This is
how the term CLI is used in this document. Tighter entry criteria, which may be used for trials
of CLI, should not be confused with the broader clinical definition.
D 6.2.3 Stratification of Patients
As in trials in IC, there are two possible reasons for stratification:
• To ensure comparability between active and control groups in terms of demographic or
other characteristics that may affect the response to treatment
• The possibility or probability that a treatment may be 0 effective only in a subgroup of the
total population
As in trials of claudication, there is no reason to stratify patients with CLI on the basis ofvari-
ables that are not known to affect outcome. Some stratification will almost certainly be neces-
sary in trials of patients with CLI. This is because, as mentioned, there is reasonable evidence
that some subgroups have a different natural history with standard therapy and that some forms
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of therapy are more likely to be effective in some subgroups. For example, the success of many
forms of interventional therapy very much depends on the site treated and the status of the run-
off. Proximal revascularizations arc more likely to be successful than distal ones. For the same
reason, as well as possibly for other reasons, amputation is more likely to be avoided in a nondi-
abetic than a diabetic patient. There is also a suggestion that patients with diabetes are likely to
behave differently in terms of cardiovascular morbidity and mortality. An alternative to stratifica-
tion is simply to perform separate trials, for instance, to exclude diabetic patients in trials of
pharmacotherapy,
Recommendation 104: Stratification in trials of patients with critical limb ischemia
Stratification should be considered for:
• patients with ulcers or gangrene (trophic changes) versus patients with rest pain alone
• diabetic versus nondiabetic patients
• morphology of arterial disease in trials of interventional therapy, in terms of both the
segment to be treated and the distal 'run-off'
• stratification for entry ankle or toe systolic pressure may be advisable in trials of
pharmacotherapy if the entry criteria are inclusive
• end-stage renal disease (already excluded from pharmacotherapy trials)
D 6.3 End Points/Outcome Reporting
D 6.3.1 Range and Assessment of Possible Primary End Points
Reliefof restpain
Relief of rest pain may be the principal aim for the patient, but it is exceedingly difficult to
assess objectively what is a purely subjective phenornenon.f The best that can be achieved is
complete relief of pain without the use of any analgesics. Any end point short of this is probably
too imprecise. In drug trials, this end point probably has to be assessed when the patient has
been off treatment for a few days to ensure that the treatment was not merely a powerful anal-
gesic.
Ulcer healing
In practice, most investigators have found this end point surprisingly difficult to assess objec-
tively. There is general agreement that a tendency to healing or reduction in ulcer size is too
difficult to assess objectively and is possibly irrelevant on its own. Total healing of the ulcer is
therefore me best definition of this end point, but even this can cause problems. There is an
observer variation in deciding whether an ulcer has healed, and blinding of the observer is
therefore essential. There is also the problem ofvariation between centers in this regard. Only
patients with "flat surface" or "transdermal" ulcers should be admitted. Ischemic cracks
between the toes or on me heel cannot be used as measurable end points. Photographic docu-
mentation of ulcer healing has proved in practice to be unsatisfactory. A possibly useful variation
in the definition of this end point is to use time to complete healing rather than the number of
healed ulcers at a particular set time.
Amputation
This is a relatively difficult end point and reflects what the patient wants to avoid. Only major
amputations, above the mid-forefoot, should be counted, and the level of amputation should be
reponed. A healed minor amputation is little handicap and is often the best that can possibly be
achieved in patients who already have gangrene of the digits. Blinding of the observer, that is,
the person making the decision to advise amputation, is desirable because there is probably vari-
ation in the level of disease and handicap at which a decision is made to advise amputation.
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Cardiovascular morbidity and total mortality
Depending on the entry criteria, between 10%and 30% of patients with eLI will have a major
nonfatal or fatal cardiovascular event over 6 to 12 months. This may be affected by a local inter-
ventional therapy, both positively and negatively. There may be a mortality or morbidity associ-
ated with the intervention. Alternatively, it is conceivable that successful intervention may
decrease overall morbidity or morality. A successful pharmacolog ical treatment for eLI also may
have a positive effect on cardiovascular morb idity and mortality. Therefore , these crucial out-
comes also need to be incorporated into the primary end point .
D 6.3.2 Choice of Primary End Point
The above end points all relate to clinical outcome, which is probably appropriate for a primary
end point. Technical outcome in intervcnrional therapies should not be a primary end point but
should be recorded as a secondary end point. The patency of a new graft or a re-opened seg-
ment using endovascular techniques is dearly relevant, but in the absence of a clinical improve-
ment, it would bc inappropriate to record it as a primary end point. A hierarchy of possible end
points is suggested .
Recommendation 105: Primary end points in trials in patients with critical limb
ischemia
The primary end point should be event-free survival. Nonfatal events include major
amputation, nonhealing of ischemic ulcers, and ischemic pain, myocardial infarction,
and ischemic stroke. In addition, the individual components of this end point should
also be reported.
D 6.3.3 Timing of Outcome Reporting
The minimum period of observation should be 6 months. Any treatment benefit that can only
be demo nstrated over a shorter period is probably not worthwhile. Longer follow-up is desir-
able and should not be a particular problem in trials of interventional therapy because there is
no continuing trial treatment. In trials of pharmacotherapy, however, there is a practical limit to
how long the treatment can be continued ; with all the close monito ring that this requires, a
treatment period of more than a year is probably not practical.
D 6.3.4 Quality of Life Assessment
A validated quality of lite assessment may be a secondar y end point. Superficially, it may be
thought that with major clinical end points such as amputation, a quality of life assessment is
less important . However, this is probably incorrect. Many patients find that their quality of life
is considerably improved after a healed major amputation compared with continuous rest pain
or ulceration , which they may have had for several months before the amputation. Limb func -
tion is an impo rtant aspect of CLI, and changes in limb function before and after treatment
should be recorded.
Critical Issue 47: Validated disease-specific quality of life instrument as a primary end
point
There is a need for a validated quality of life instrument as a possible primary end point
in the treatment of critical limb ischemia , because none currently exists, and comorbidi-
ties tend to obscure the impact of treatment.
D 6.3.5 Economic Evaluation
This is particularly impo rtant in this area because of the major costs involved in treating CLI
and in supporting patients who have had an amputation. Various methodologies have been used
to calculate the cost-effectiveness of various types of intervention in CLI, and the complicated
technical issues raised are discussed in more detail in D 5.1.2, Costs of Treatment for Critical
Limb Ischemia, p 5275 ). The methodolo gy for cost analysis in a trial should be set out in the
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protocol and should be prospective. Patient groups should be compared on an intent-to-treat
basis, and costs should be computed over the entire duration of the study. The outcome of the
cost analysis can be set out much more meaningfully in CLI than in trials of IC, for example, by
calculating the cost of saving one fully functional leg for 1 year.
Reconunendation 106: Selected secondary end points in trials in patients with critical
limb ischemia
Quality of life instruments ideally should be used in all trials.
The methodology for cost analysis in the trial should be set out in the protocol and
should be prospective.
Changes in limb function before and after treatment
If the primary end point is a composite end point, the components should be evaluated
individually as secondary end points.
If not used as primary end points, cardiovascular morbidity and mortality as well as
total mortality should be assessed individually as secondary end points to ensure the
collection of appropriate safety information.
D 6.4 Special Issues Relating to Interventional Trials
Comparative trials of interventional therapy, either surgical or endovascular, have a number of
inherent problems that do not exist in trials of pharmacotherapy. This is undoubtedly one rea-
son why comparative trials of interventional therapy have been rare.
D 6.4.1 Operator Variability
The delivery of the intervention cannot be standardized in the same way as a medication. Not
only is the technical skill of the operator crucial, but often it is impossible to use the same oper-
ator, even within a single center, to deliver the two alternative therapies. For instance, although
the same surgeon can perform an in situ and a reversed vein bypass, if the comparison is
between a surgical bypass and an endovascular procedure, then different operators will be
involved. The fact that an operator is required at all makes blinding of the treatment delivery
impossible. The problem is compounded by the fact that in a multi-center trial, a number of
different operators, with differing skills,will be required. This also raises the issue of the applica-
bility of an interventional trial result to general practice.
Frequently, a new procedure is performed by an enthusiast who has spent considerable time and
effort in developing that technique. Results are likely to be much superior to those that would
be achieved by his or her colleagues who try to adopt the technique. There are many examples
of initial results with a new technique from a particular center being far superior to the results
subsequently recorded with the same technique in regional or national audits.
D 6.4.2 Importance of Additional Variables in the Entry Criteria
In intervention trials, the local morphology of the lesion to be treated is of paramount impor-
tance in determining the result. In general, reconstruction of proximal arteries will be more
durable than reconstructions of distal arteries. Run-off morphology also has to be considered,
because, even though the treated lesion may be situated in the femoral artery, there is a great
difference between finding just collaterals or three patent vessels at the crural level. It is essential
to define these variables in the trial and either stratify the patients accordingly or only include
patients with particular characteristics (see Recommendation 107, p 5287).
D 6.4.3 Adjuvant Pharmacotherapy in Clinical Trials
There has been an increasing tendency to try to improve the results of interventional treatment
by some form of adjuvant pharmacotherapy to prevent both early failure attributable to throm-
bosis and later failures caused by neointimal hyperplasia. If a particular adjuvant therapy, for
instance, full anticoagulation immediately after stent placement, has been shown to be probably
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D 6.5.2
beneficial, then it should be applied as background treatment to all trial patients. Problems arise
when evidence of the efficacy of adjuvant therapy is inconsistent, for instance, in the use of
antiplatelet drugs long-term after vein bypass grafts. The principle of applying all standard pro-
cedures that may improve the result to both the treatment and the control group also applies to
issues such as graft surveillance, which has been shown to improve long-term patency.
Recommendation 107: Reporting standards in interventional trials in patients with criti-
cal limb ischemia
The recommendations of the committee on Reporting Standards of the SVSjISCVS, and
in the case of new devices the standards of the Technology Assessment Committee of the
SCVIR, should be adopted where appropriate in trials involving patients with CLI.
Special Issues Relating to Drug Trials in eLI
Patients Entered
The issues discussed under Entry Criteria (D 6.2, P S282) apply here. In virtually all trials of
stand-alone pharmacotherapy for treatment of CLI, only those patients have been entered who
already had some form of interventional treatment-often several-that have all failed, or in
whom interventional treatment is technically impossible. Therefore, the patients entered tend to
be at an end-stage of CLI. This will be further exacerbated if tight inclusion criteria are used in
terms of Doppler systolic pressure or TCP02. The net result is often that most patients entered
into these trials are probably beyond salvage by any therapy. Inclusion of patients who have not
reached end-stage CLI would be of importance, although comparative trials between interven-
tions and pharmacotherapy are probably not yet appropriate.
Analysis of Secondary Interventions
Although suitability for some form of reconstructive surgery is usually an exclusion criteria in
these trials, in practice some patients who deteriorate during the period of the trial do undergo
some form of interventional treatment. The explanation is probably that the interventional
treatment is high risk, and therefore the doctor in charge preferred to avoid it in the hope that a
pharmacological intervention may work. However, when this does not occur, then a last-resort
procedure is performed. Another explanation may be that variation exists between surgeons and
centers concerning the suitability of a specific lesion for intervention. Such circumstances can
cause considerable difficulty in analyzing the outcome of the trial on an intention-to-treat basis.
It is conceivable that the patients randomized to the active drug deteriorate more quickly than
the control group. Therefore, more patients in the active group will receive some form ofinter-
ventional therapy, and if this is successful, then on an intention-to-treat basis, the active drug
could wrongly appear to be effective.
Alternatively, it is possible that the test drug provides no benefit alone but is an effective adju-
vant to interventions. If a large proportion of patients undergo some form of intervention, then
a positive result to the trial could misleadingly suggest that the drug is effective on its own.
Subgroup analysis considering specificallythe patients not undergoing secondary intervention is,
under these circumstances, necessary.
D 6.5.3 Other Issues
Cardiovascular events
Drug therapy for CLI is usually administered systemically and, for reasons already explained,
possibly may also benefit the patient in terms of nonfatal or fatal cardiovascular events.
However, the contrary also may be true, and the drug treatment may precipitate cardiovascular
events. The issue of stopping rules in the event of an excess in cardiovascular events in one of
the trial groups is an important issue in drug trials.
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Effect in contralateral leg
The systemic effect of drug treatment also raises the issue of how to deal with a change in the
contralateral leg. (This can clearly be ignored when looking at interventional therapy in one
leg.) Although entry into a drug trial should be on the basis of an index leg, changes in the
contralateral side during the course of the treatment cannot be ignored. The primary clinical
end points described in D 6.3.2, Choice of Primary End Point, p 5285) must apply to both
legs. If a drug treatment heals the ulcer on the index leg, but during the same period the
patient develops an ulcer on the other leg, then the drug treatment cannot be considered to
have been successful.
Side effects
Many of the drugs used in trials of pharmacotherapy in CLI have obvious, albeit not dangerous,
side effects. For instance, prostacyclin analogs often produce flushing, headaches, or nausea.
This raises the question of the completeness of the blinding of the investigator or observer.
Active drug control
Active drug control may be considered if the comparator drug has consistently been shown to
be superior to placebo and if the magnitude of its effect is generally accepted by the medical
community.
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